Liver-focused chemo for metastatic colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests giving high-dose melphalan directly into the liver's blood supply, followed by standard cancer therapy, for people whose colorectal cancer has spread mainly to the liver. The goal is to see if this approach is safer and works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your colorectal cancer has spread to the liver, and most of your tumor burden is there
- You have tried and progressed on or couldn't tolerate standard chemotherapies and targeted therapies
- Your overall health is good (ECOG score 0 or 1)
- You do not have serious liver or heart conditions, active infections, or other cancers
- You are not currently on blood thinners that can't be paused
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
Hear when a new Refractory Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.